GADICKE ANSBERT’s insider transaction report records MPM BioVentures 2014, L.P. selling 86,482 Entrada Therapeutics shares across transactions dated 2026-09-01 through 2026-09-03. The disclosed activity matters to investors because it pairs prices of $7.06 to $7.19 per share with remaining ownership of 4,144,952 shares.

Key Highlights

  • MPM BioVentures 2014, L.P. sold Entrada Therapeutics shares at prices ranging from $7.06 to $7.19 per share.
  • The Partnership owned 4,144,952 Entrada Therapeutics shares after the transactions.
  • The seller is identified as an insider of Entrada Therapeutics, Inc.

GADICKE ANSBERT’s insider transaction report records MPM BioVentures 2014, L.P. selling 86,482 shares of Entrada Therapeutics, Inc (NASDAQ: TRDA). The transactions involved an insider position and left the partnership with a disclosed ownership balance after the sales.

Entrada Shares Sold Across September Transactions

The sales were carried out under SEC transaction code S. Prices for the transactions ranged from $7.06 to $7.19 per share. The activity took place between 1 September 2026 and 3 September 2026. The reported sales covered separate transactions during that period. Each price was stated on a per-share basis, while the 86,482 figure represents the total number of Entrada Therapeutics shares sold.

The transaction information therefore identifies both the shares sold and the post-sale ownership reported for the insider partnership.